– ISRAEL – LabStyle Innovations Corp. (OTCQB:DRIO), developer of the Dario™ Diabetes Management Solution, today announced the appointment of Professor Richard B. Stone as an independent member of its Board of Directors.
Prof. Stone brings over forty-five years of legal and business experience to LabStyle as an entrepreneur, venture capitalist public, company officer and director, and legal and corporate governance expert. He currently serves on the board of directors of multiple technology companies, including Powermat, Espro-Accoustiguide Group, Wellsense Technologies, NanoX Imaging and Check-Cap. Among his other public company experiences, Prof. Stone cofounded Lev Pharmaceuticals, Inc. which was sold to ViroPharma in 2008 for nearly $450 million in upfront consideration.
Prof. Stone is presently and has since 1974 served as a professor at Columbia Law School, specializing in tax law and business planning, and previously served as an Assistant Solicitor General of the United States. He also served as Chairman of the Conference of Presidents of Major American Jewish Organizations. He is a graduate of Harvard University and Harvard Law School.
“We are very excited to have someone with Richard’s extensive experience and credentials, particularly in the medical and technology industries, join our Board of Directors,” said Dr. Oren Fuerst, LabStyle’s Chairman of the Board. “As we continue to grow and expand Dario into new markets, Richard will be an incredible asset allowing us to draw on his vast knowledge of law as well as managing and financing companies. In addition, his corporate governance experience will be particularly helpful to us, and we expect that he will be an active member of our independent board committees.”
“I’m very excited to be joining the team that has created Dario, which promises to make a notable difference in the lives of people with diabetes,” said Prof. Stone. “I believe this innovative technology has amazing potential, and I look forward to playing a direct role in helping LabStyle achieve its operational and corporate goals.”
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dario™ Diabetes Management Solution, a mobile, cloud-based, diabetes management solution which includes novel software applications combined with a stylish, ‘all-in-one’, pocket-sized, blood glucose monitoring device. Dario™ received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario™ Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services and in April 2014, LabStyle received a Notice of Allowance for a U.S. patent covering core functions of the Dario™ Blood Glucose Monitoring System.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.